DAMORA THERAPEUTICS, INC. (DMRA) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $931.65M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $732.00K; Retained Earnings (Accumulated Deficit)USD $-546.32M.
- 2026-03-31: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $893.54M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $754.00K; Retained Earnings (Accumulated Deficit)USD $-515.15M.
- 2025-12-31: Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD $310.69M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $802.00K; Retained Earnings (Accumulated Deficit)USD $-487.36M.
- 2025-09-30: Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD $292.47M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $823.00K; Retained Earnings (Accumulated Deficit)USD $-286.63M.
DAMORA THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.00K | $931.65M | $732.00K | $-546.32M | $516.06M | 3 month · $6.14M 6 month · $9.28M |
| 2026-03-31 | $1.00K | $893.54M | $754.00K | $-515.15M | $511.60M | 3 month · $3.13M |
| 2025-12-31 | (m) | $310.69M | $802.00K | $-487.36M | $240.38M | 12 month · $998.00K |
| 2025-09-30 | (m) | $292.47M | $823.00K | $-286.63M | $8.01M | 3 month · $164.00K 9 month · $515.00K |
| 2025-06-30 | (m) | $292.30M | $809.00K | $-283.49M | $10.95M | 3 month · $172.00K 6 month · $351.00K |
| 2025-03-31 | (m) | $292.11M | $300.00K | $-280.06M | $13.71M | 3 month · $179.00K |
| 2024-12-31 | (m) | $291.90M | $97.00K | $-277.52M | $15.83M | 12 month · $3.24M |
| 2024-09-30 | (m) | $291.05M | $665.00K | $-270.78M | $20.93M | 3 month · $681.00K 9 month · $2.93M |
| 2024-06-30 | (m) | $290.29M | $197.00K | $-266.90M | $23.59M | 3 month · $891.00K 6 month · $2.25M |
| 2024-03-31 | (m) | $289.39M | $326.00K | $-261.56M | $28.16M | 3 month · $1.36M |
| 2023-12-31 | (m) | $288.04M | $380.00K | $-256.08M | $32.33M | 12 month · $5.43M |
| 2023-09-30 | (m) | $286.95M | $46.00K | $-249.61M | $37.38M | 3 month · $1.46M 9 month · $4.34M |
| 2023-06-30 | (m) | $285.31M | $-137.00K | $-241.47M | $43.70M | 3 month · $1.44M 6 month · $2.87M |
| 2023-03-31 | (m) | $281.19M | $-127.00K | $-230.73M | $50.33M | 3 month · $1.43M |
| 2022-12-31 | (m) | $279.73M | $-244.00K | $-217.74M | $61.75M | 12 month · $5.57M |
| 2022-09-30 | (m) | $278.32M | $-1.93M | $-203.67M | $72.73M | 3 month · $1.40M 9 month · $4.22M |
| 2022-06-30 | (m) | $276.50M | $-1.50M | $-189.94M | $85.06M | 3 month · $1.42M 6 month · $2.82M |
| 2022-03-31 | (m) | $275.06M | $-695.00K | $-173.05M | $101.31M | 3 month · $1.40M |
| 2021-12-31 | (m) | $273.65M | $-320.00K | $-156.11M | $117.22M | 12 month · $4.48M |
| 2021-09-30 | (m) | $272.41M | $-89.00K | $-142.70M | $129.62M | 3 month · $1.22M 9 month · $3.24M |
| 2021-06-30 | (m) | $271.19M | $246.00K | $-130.01M | $141.43M | 3 month · $987.00K 6 month · $2.02M |
| 2021-03-31 | (m) | $270.21M | $70.00K | $-117.70M | $152.57M | 3 month · $1.03M |
| 2020-12-31 | (m) | $269.18M | $674.00K | $-104.36M | $165.49M | 12 month · $1.01M |
| 2020-09-30 | (m) | $1.36M | $-315.00K | $-92.78M | $-91.74M | 3 month · $134.00K 9 month · $535.00K |
| 2020-06-30 | (m) | (m) | (m) | (m) | $-82.55M | 3 month · $401.00K 6 month · $401.00K |
| 2020-03-31 | (m) | (m) | (m) | (m) | $-77.03M | (m) |
| 2019-12-31 | (m) | $826.00K | $-2.45M | $-69.52M | $-71.15M | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | $-48.06M | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | $-41.89M | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | $-33.84M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |